References

Masld: a systemic metabolic disorder with cardiovascular and Malignant complications

10.1136/gutjnl-2023-330595 · 2024 · External reference

Non-alcoholic fatty liver disease

10.1016/s0140-6736(20)32511-3 · 2021 · External reference

Epidemiology of metabolic dysfunction-associated steatotic liver disease

10.3350/cmh.2024.0431 · 2025 · External reference

Epidemiology of metabolic dysfunction-associated steatotic liver disease in South Asian ethnicities: a systematic review and meta-analysis

10.1111/jgh.70080 · 2025 · External reference

Trends in the prevalence of steatotic liver disease among Chinese adults 2015-2023: a nationwide cross-sectional study

10.1097/hc9.0000000000000785 · 2025 · External reference

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis

10.1038/s41573-024-01084-2 · 2025 · External reference

Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity

10.1038/ncomms12977 · 2016 · External reference

Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease

10.1016/j.cmet.2024.04.006 · 2024 · External reference

Unraveling the regulation of hepatic metabolism by insulin

10.1016/j.tem.2017.03.003 · 2017 · External reference

Trends in insulin resistance: insights into mechanisms and therapeutic strategy

10.1038/s41392-022-01073-0 · 2022 · External reference

Diabetes and metabolic dysfunction-associated fatty liver disease

10.1016/j.metabol.2021.154868 · 2021 · External reference

Hepatokines linking nonalcoholic fatty liver disease and insulin resistance

10.1038/nrendo.2017.56 · 2017 · External reference

Impact of lipids on insulin resistance: insights from human and animal studies

10.2147/dddt.s468147 · 2024 · External reference

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

10.1038/s41575-021-00502-9 · 2021 · External reference

Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

10.1007/s00125-005-1682-x · 2005 · External reference

The association between non-alcoholic fatty liver disease and insulin resistance within normal glucose level population

10.1016/s0168-8278(22)00704-8 · 2022 · External reference

Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction-associated steatohepatitis

10.1126/sciadv.ado3141 · 2024 · External reference

Monocyte bioenergetics: an immunometabolic perspective in metabolic dysfunction-associated steatohepatitis

10.1016/j.xcrm.2024.101564 · 2024 · External reference

Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD

10.1210/clinem/dgac660 · 2023 · External reference

Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: results of multimodality assessment using both conventional and digital pathology

10.1097/hep.0000000000000980 · 2025 · External reference

Prevent and reverse metabolic dysfunction-associated steatohepatitis and hepatic fibrosis via mRNA-mediated liver-specific antibody therapy

10.1021/acsnano.4c13404 · 2024 · External reference

Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis

10.1038/s41467-024-48317-x · 2024 · External reference

HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients

10.1038/s41598-025-15425-7 · 2025 · External reference

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity

10.2337/diacare.23.1.57 · 2000 · External reference

Insulin resistance index (HOMA-IR) in the differentiation of patients with non-alcoholic fatty liver disease and healthy individuals

10.1590/s0004-28032010000200009 · 2010 · External reference

Insulin resistance/sensitivity measures as screening indicators of metabolic-associated fatty liver disease and liver fibrosis

10.1007/s10620-024-08309-9 · 2024 · External reference

The mediation effects of type 2 diabetes mellitus and related biomarkers on the association of metabolic dysfunction-associated steatotic liver disease and fibrosis

10.15403/jgld-5901 · 2025 · External reference

Association between HOMA-IR and metabolic dysfunction-associated steatohepatitis in US adults with MASLD

10.1016/j.metop.2025.100402 · 2025 · External reference

HOMA-IR as a predictor of health outcomes in patients with metabolic risk factors: a systematic review and meta-analysis

10.1007/s40292-022-00542-5 · 2022 · External reference

Hs-CRP and HOMA-IR: include them in the MASLD definition or treat them as mediators between MASLD and atherosclerotic cardiovascular disease

10.1016/j.jhep.2024.08.005 · 2025 · External reference

Baseline HOMA IR and circulating FGF21 levels predict NAFLD improvement in patients undergoing a low carbohydrate dietary intervention for weight loss: a prospective observational pilot study

10.3390/nu12072141 · 2020 · External reference

The emerging role of glucagon-like peptide-1 receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis

10.1016/j.cgh.2024.01.032 · 2024 · External reference

The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

10.1038/s41467-024-47919-9 · 2024 · External reference

Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: a phase II, randomized, double-blind, placebo-controlled study

10.1097/hep.0000000000001475 · 2026 · External reference

Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease: a population based study

10.1016/j.jdiacomp.2015.11.019 · 2016 · External reference

Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease

10.1186/s12933-024-02263-6 · 2024 · External reference

Correlation analysis of the triglyceride-glucose index and related parameters in metabolic dysfunction-associated fatty liver disease

10.1038/s41598-024-84809-y · 2025 · External reference

Comparison of ten surrogate insulin resistance and obesity markers to identify metabolic syndrome in Mexican adults

10.3390/metabo14070358 · 2024 · External reference

Triglyceride glucose-related indexes and lipid accumulation products: reliable markers of insulin resistance in the Chinese population

10.3389/fnut.2024.1373039 · 2024 · External reference

Predictive value of TyG and TyG-BMI indices for non-alcoholic fatty liver disease in high-altitude regions of China: a cross-sectional study

10.3390/jcm13237423 · 2024 · External reference

Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: triglyceride glucose index-related parameters

10.3389/fendo.2022.951689 · 2022 · External reference

Association of insulin resistance indicators with hepatic steatosis and fibrosis in patients with metabolic syndrome

10.1186/s12876-023-03095-6 · 2024 · External reference

Association between triglyceride-glucose related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK Biobank

10.1186/s12933-024-02572-w · 2025 · External reference

Diagnosis of metabolic dysfunction-associated steatotic liver disease by triglyceride glucose-body mass index: a systematic review and meta-analysis

10.1016/j.aohep.2025.102122 · 2025 · External reference

Association of triglyceride glucose-body mass index with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis

10.1371/journal.pone.0324483 · 2025 · External reference

Association between triglyceride-glucose related indices and severe infection requiring hospital admission or resulting in mortality among individuals with metabolic dysfunction-associated steatotic liver disease

10.1016/j.clnu.2025.04.006 · 2025 · External reference

Comprehensive genetic study of the insulin resistance marker TG:HDL-C in the UK Biobank

10.1038/s41588-023-01625-2 · 2024 · External reference

Impact of inflammatory and insulin resistance biomarkers on long-term risks in coronary heart disease patients with cardiovascular-kidney-metabolic syndrome

10.1161/circ.150.suppl_1.4140042 · 2024 · External reference

Application of TG/HDL-C combined with liver function indexes to predict metabolic-associated fatty liver disease

10.12182/20220960102 · 2022 · External reference

Association between triglyceride to high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease and liver fibrosis in American adults: an observational study from the National Health and Nutrition Examination Survey 2017-2020

10.3389/fendo.2024.1362396 · 2024 · External reference

Triglyceride to HDL cholesterol ratio for the identification of MASLD in obesity: a liver biopsy-based case-control study

10.3390/nu16091310 · 2024 · External reference

TG/HDL-C ratio is positively associated with risk and severity of CHD among NAFLD patients: a case control study

10.3389/fendo.2024.1383489 · 2024 · External reference

Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001-2018

10.1186/s12933-024-02334-8 · 2024 · External reference

METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes

10.1530/eje-17-0883 · 2018 · External reference

The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults

10.3350/cmh.2022.0099 · 2022 · External reference

METS-IR/HOMA-IR and MAFLD in US adults: dose-response correlation and the effect mediated by physical activity

10.1186/s12902-024-01646-w · 2024 · External reference

Identification of pediatric MASLD using insulin resistance indices

10.1016/j.jhepr.2025.101419 · 2025 · External reference

Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences

10.1038/s41598-025-10765-w · 2025 · External reference

Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids

10.3389/fendo.2023.1224967 · 2023 · External reference

Dose-response associations of metabolic score for insulin resistance index with nonalcoholic fatty liver disease among a nonobese Chinese population: retrospective evidence from a population-based cohort study

10.1155/2022/4930355 · 2022 · External reference

Use of metabolic scores and lipid ratios to predict metabolic dysfunction-associated steatotic liver disease onset in patients with inflammatory bowel diseases

10.3390/jcm14092973 · 2025 · External reference

Non-linear association between metabolic score for insulin resistance and nonalcoholic fatty liver disease: analysis of US National Health and Nutrition Examination Survey data, 2017-2020

10.1186/s12902-025-01988-z · 2025 · External reference

Insulin resistance, non-alcoholic fatty liver disease and type 2 diabetes mellitus: clinical and experimental perspective

10.4093/dmj.2023.0350 · 2024 · External reference

Unraveling the mystery of insulin resistance: from principle mechanistic insights and consequences to therapeutic interventions

10.3390/ijms26062770 · 2025 · External reference